Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Use of a force-sensing automated open field apparatus in a longitudinal study of multiple behavioral deficits in CAG140 Huntington's disease model mice.

Fowler SC, Muma NA.

Behav Brain Res. 2015 Nov 1;294:7-16. doi: 10.1016/j.bbr.2015.07.036. Epub 2015 Jul 22.

PMID:
26210937
2.

Striatal synaptosomes from Hdh140Q/140Q knock-in mice have altered protein levels, novel sites of methionine oxidation, and excess glutamate release after stimulation.

Valencia A, Sapp E, Kimm JS, McClory H, Ansong KA, Yohrling G, Kwak S, Kegel KB, Green KM, Shaffer SA, Aronin N, DiFiglia M.

J Huntingtons Dis. 2013;2(4):459-75.

3.

Striatal pre-enkephalin overexpression improves Huntington's disease symptoms in the R6/2 mouse model of Huntington's disease.

Bissonnette S, Vaillancourt M, Hébert SS, Drolet G, Samadi P.

PLoS One. 2013 Sep 11;8(9):e75099. doi: 10.1371/journal.pone.0075099. eCollection 2013.

4.

Extracts of adipose derived stem cells slows progression in the R6/2 model of Huntington's disease.

Im W, Ban J, Lim J, Lee M, Lee ST, Chu K, Kim M.

PLoS One. 2013;8(4):e59438. doi: 10.1371/journal.pone.0059438. Epub 2013 Apr 2.

5.

Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice.

Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, Lee VM.

Science. 2012 Nov 16;338(6109):949-53. doi: 10.1126/science.1227157.

6.

Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice.

Garriga-Canut M, Agustín-Pavón C, Herrmann F, Sánchez A, Dierssen M, Fillat C, Isalan M.

Proc Natl Acad Sci U S A. 2012 Nov 6;109(45):E3136-45. doi: 10.1073/pnas.1206506109. Epub 2012 Oct 10.

7.

Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.

Switonski PM, Szlachcic WJ, Gabka A, Krzyzosiak WJ, Figiel M.

Mol Neurobiol. 2012 Oct;46(2):430-66. doi: 10.1007/s12035-012-8316-3. Epub 2012 Sep 4. Review.

8.

Implantation of undifferentiated and pre-differentiated human neural stem cells in the R6/2 transgenic mouse model of Huntington's disease.

El-Akabawy G, Rattray I, Johansson SM, Gale R, Bates G, Modo M.

BMC Neurosci. 2012 Aug 9;13:97. doi: 10.1186/1471-2202-13-97.

9.

Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins.

Butler DC, McLear JA, Messer A.

Prog Neurobiol. 2012 May;97(2):190-204. doi: 10.1016/j.pneurobio.2011.11.004. Epub 2011 Nov 18. Review.

10.

Gene therapy in mouse models of huntington disease.

Southwell AL, Patterson PH.

Neuroscientist. 2011 Apr;17(2):153-62. doi: 10.1177/1073858410386236. Review.

11.

Modeling pathogenesis of Huntington's disease with inducible neuroprogenitor cells.

Dong G, Ferguson JM, Duling AJ, Nicholas RG, Zhang D, Rezvani K, Fang S, Monteiro MJ, Li S, Li XJ, Wang H.

Cell Mol Neurobiol. 2011 Jul;31(5):737-47. doi: 10.1007/s10571-011-9679-0. Epub 2011 Mar 31.

12.

Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy.

Brunden KR, Zhang B, Carroll J, Yao Y, Potuzak JS, Hogan AM, Iba M, James MJ, Xie SX, Ballatore C, Smith AB 3rd, Lee VM, Trojanowski JQ.

J Neurosci. 2010 Oct 13;30(41):13861-6. doi: 10.1523/JNEUROSCI.3059-10.2010.

13.

Early or late-stage anti-N-terminal Huntingtin intrabody gene therapy reduces pathological features in B6.HDR6/1 mice.

Snyder-Keller A, McLear JA, Hathorn T, Messer A.

J Neuropathol Exp Neurol. 2010 Oct;69(10):1078-85. doi: 10.1097/NEN.0b013e3181f530ec.

14.

Phospholipase C, Ca2+, and calmodulin signaling are required for 5-HT2A receptor-mediated transamidation of Rac1 by transglutaminase.

Dai Y, Dudek NL, Li Q, Muma NA.

Psychopharmacology (Berl). 2011 Feb;213(2-3):403-12. doi: 10.1007/s00213-010-1984-7. Epub 2010 Aug 18.

Items per page

Supplemental Content

Write to the Help Desk